CONNECT WITH US:
May, 22 2017 12:00 JST
Singapore eDevelopment Ltd
Singapore eDevelopment Subsidiary Initiates Research on New Universal Drug Platform
- Nobel Prize nominee Daryl Thompson to lead research, conducted by subsidiary Global BioLife Inc., supported by Charles River Laboratories
- Six month target for validating lab data, twelve month target for completion of platform
SINGAPORE, May, 22 2017 - (ACN Newswire) - Singapore eDevelopment Ltd ("SeD") subsidiary Global BioLife Inc. has initiated advanced research on a new universal therapeutic drug platform known as Linebacker, to combat a range of diseases including Alzheimer's, diabetes and cancer. The research will be led by two-time Nobel Prize nominee Mr Daryl Thompson.
SGX-listed SeD (SP:SGE) said Mr Thompson would leverage his expertise in organic and carbohydrate chemistry and the use of pandemic technology in combating the Ebola virus in the development of Linebacker. Unlike traditional approaches to curing individual diseases with specific drugs, the Linebacker platform seeks a breakthrough option for multiple diseases to be cured. It can also potentially combat drug-resistant viruses and antibiotic-resistant bacteria.
Mr Thompson will lead the research, to be conducted by Global BioLife, in his capacity as Director of Scientific Initiatives. Global BioLife is an 80%-held subsidiary of SeD's wholly-owned subsidiary, Global BioMedical Inc. The remaining stake in Global BioLife is held in equal proportions by Mr Thompson's GRDG Sciences LLC and ASX-listed Holista CollTech Limited.
Mr Thompson was nominated for a Nobel Prize in 2015 and 2016 for his research in cutting-edge organic and carbohydrate chemistry as well his research in pandemics technology to fight pandemics such as Ebola. He has used his expertise to initiate research regarding universal therapeutics to cure the world's deadliest diseases. Mr Scott Truesdell, Research Coordinator and Special Projects Leader at Global BioLife, will execute the research on the Linebacker platform.
Global BioLife has engaged NYSE-listed Charles River Laboratories International, Inc., which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.
Mr Thompson said, "We expect to obtain validating laboratory data from the universal therapeutic drug platform within the first six months and are targeting for the platform itself to be completed within twelve months. We have a unique patented technology and are already getting interest from Big Pharma players and venture capitalists. This interest will rise as the validating data becomes available."
"Global BioLife recognizes the need for affordable cures to emerging pandemics and we will leverage the team's deep expertise to develop this new universal therapeutic drug platform," said Dr Tang Peihong, Global BioLife Director and CEO. Dr Tang has a Ph.D. in Chemical Engineering and was selected as National Distinguished Expert in China's Thousand Talents Plan in 2012.
GRDG Sciences LLC is a natural products discovery drug research company formed in Florida, USA by Mr Thompson, a natural products scientist. GRDG Sciences works with multiple global institutions such as Charles River. Holista CollTech Ltd is a research-driven biotech company that resulted from the merger of Holista Biotech Sdn Bhd and CollTech Australia Ltd. It is dedicated to delivering first-class natural ingredients and wellness products (www.holista.com).
About Singapore eDevelopment Limited
Incorporated on 9 September 2009, and listed on the Singapore Exchange Catalist (SGX:40V) in July 2010 (SP: SGE; SINE), Singapore eDevelopment is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) Information Technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg.
Issued on behalf of the Company:
WeR1 Consultants Pte Ltd
Mr Ian Lau
T: +65 6737 4844
Source: Singapore eDevelopment Ltd
Sectors: Investors/Exchanges, Daily Finance, BioTech, HealthCare, Alternatives
Copyright ©2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
DENSO Recognized with "Friend of ASEAN Award" at the ASEAN Business Awards (ABA) 2019
Nov 11, 2019 17:07 JST
Lexus Electric Debuts in China
Nov 11, 2019 16:38 JST
Fujitsu Expands Mid-career Recruitment
Nov 11, 2019 10:33 JST
Double Shanghai Podium for TOYOTA GAZOO Racing
Nov 11, 2019 09:11 JST
TOYOTA GAZOO Racing goes all-in for another title in Australia
Nov 08, 2019 19:33 JST
Honda Releases Consolidated Financial Summary for the Fiscal 2nd Quarter Ended September 30, 2019
Nov 08, 2019 15:09 JST
Mitsubishi Model A Selected as Historic Car by JAHFA
Nov 08, 2019 14:49 JST
BYD, Toyota Agree to Establish Joint Company for Battery Electric Vehicle Research and Development
Nov 07, 2019 19:12 JST
MITSUBISHI MOTORS Restyles Mirage and Attrage Compact Models
Nov 07, 2019 11:58 JST
Hitachi and Centre Leon Berard Cancer Center in Lyon to Launch a Research Collaboration in the Fight Against Cancer with AI
Nov 07, 2019 07:25 JST
Fujitsu Improves Efficiency in Cancer Genomic Medicine in Joint AI Research with the Institute of Medical Science at the University of Tokyo
Nov 07, 2019 05:09 JST
ULVAC launches Smartphone-Direct Pirani Gauge "SWU10-U"
Nov 06, 2019 17:00 JST
Showa Denko (SDK) Announces 2019 Third Quarter Financial Results
Nov 06, 2019 16:00 JST
NEC Showcases Industry-leading Digital Finance Solutions at Inaugural SFF X Switch 2019
Nov 06, 2019 15:11 JST
Suzhou Tongji Blockchain Research Institute and Fujitsu Research and Development Center start Research Collaboration on Blockchain Technology
Nov 06, 2019 11:45 JST
Fujitsu Delivers Next-Generation Storage Performance for the Digital World
Nov 05, 2019 19:09 JST
Upgraded Version of Tokyo Stock Exchange's "arrowhead" Trading System
Nov 05, 2019 16:01 JST
MITSUBISHI MOTORS' Brand New Crossover MPV Coming Soon in Indonesia
Nov 05, 2019 13:01 JST
Toyota Launches the New "Raize" in Japan
Nov 05, 2019 11:05 JST
Eisai Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibitor Tazemetostat to Royalty Pharma
Nov 05, 2019 10:02 JST
More Latest Release >>
Global BioLife to present Functional Fragrance Formula at the American Society for Microbiology's Biothreats Conference as a New Method to Prevent and Treat Tuberculosis
October 29 2019 09:00 JST
Global BioLife unveils naturally modified Laetose at Harvard Global Catalyst Health Summit
July 24 2019 15:00 JST
Global BioLife's 3F Mosquito Repellent Formula performs well in Independent Testing
June 12 2019 14:00 JST
Global BioLife's 3F Antimicrobial Fragrance shows Efficacy against Tuberculosis
January 28 2019 12:00 JST
Singapore eDevelopment's Global BioLife to present Parkinson's Research at Neuroscience 2018
November 07 2018 19:00 JST
Singapore eDevelopment Limited Announces Corporate and Business Update
June 18 2018 19:00 JST
Singapore eDevelopment's Global BioLife develops Low Glycemic Modified Sugar
May 31 2018 18:00 JST
Singapore eDevelopment's Global BioLife confirms LB2 efficacy against Ebola
March 01 2018 14:00 JST
Singapore eDevelopment's Global BioLife confirms 100% Repellency of 3F Mosquito Fragrance
November 01 2017 18:00 JST
Singapore eDevelopment's Global BioLife develops Low-GI Modified Sugar
October 24 2017 18:00 JST
More Press release >>